Page 24 - Vaccine

World Coronavirus Dispatch: Lessons from Japan on post-pandemic recovery

Shanghai outbreak traced to cargo from North America, many nations shunning skilled foreign workers, the speed at which Oxford vaccine was developed and other pandemic-related news acorss the globe

How sophisticated mRNA vaccines from Pfizer, Moderna are and how they work?

Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad

Common OCD drug may be used in early treatment for Covid-19, say scientists

In the study, the 152 trial participants, all of whom were 18 years or older, were diagnosed with mild forms of Covid-19

Vaccine alliance raises $2 billion to buy Covid-19 shots for poor nations

Berkley said $3 billion was still needed for diagnostics and $6.1 billion for therapeutics by the end of 2021

Interim trial results show Sputnik V Covid-19 vaccine 92% effective: Russia

Pfizer Inc and BioNTech said on Monday their shot was more than 90% effective

Pfizer, BioNTech say their Covid-19 vaccine is more than 90% effective

Pfizer and BioNTech SE are first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine

Is global logistics industry prepared to deliver Covid vaccines? Not quite

The preparedness of those responsible for moving the medicine from manufacturing sites to health clinics worldwide is paramount because the doses, once in transit, must stay ultra-cold

China planning to inject students with Covid-19 vaccines yet to be approved

The two shots being developed by CNBG -- which are still in the final, third phase of testing -- were authorized for emergency use in China

Facebook bans anti-vaccination ads but not anti-vaccination posts

Facebook says it will ban ads on its platform that discourage vaccinations with an exception carved out for advocacy ads about government vaccine policies

Govt begins micro-planning for administering Covid-19 vaccine to the masses

Centre has asked states to update databases, train manpower, indicate resource requirements

World Coronavirus Dispatch: China seeks to have its vaccine assessed by WHO

Germany's new cases rise most since mid-April, Singapore rushes to open borders, UK's Sunak says jobs a bigger priority than tax rise, and other pandemic-related news across the globe

Covid-19 vaccine: Bharat Biotech to use Kansas firm's adjuvant for Covaxin

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed

Indigenous players on a slow and steady coronavirus vaccine race

Smaller players are bullish on playing crucial role in nation's vaccine infrastructure

India Coronavirus Dispatch: Delhi sees a slowdown in daily new cases

High infection rates across prisons, one in four people not wearing masks, mid-day meals impacted as schools and anganwadis remain shut--news on how the country is coping with the pandemic

How Russia shortened the Covid-19 vaccine race to declare victory

For years, Putin has pushed to rebuild Russia's prowess in long-neglected life sciences

ICMR launches a new vaccine portal for Covid, with details of trials

The portal covers other ailments as well; will provide details of progress made locally and globally at regular intervals

Journey from lab to jab: Complex process of getting approval for a vaccine

While the govt is in a hurry to get one for Covid, all vaccines, domestic or imported, must follow strict rules. Business Standard takes you through a carefully drawn journey of vaccine development

Bharat Biotech aims at billion Covaxin doses a year, phase-3 trials in Oct

Firm also ties up with Washington University's school of medicine for intransal vaccine for Covid-19

World Coronavirus Dispatch: Airlines urge mandatory tests to prop demand

Fujifilm to seek nod for Covid drug, UK economy faces gloomy fourth quarter, Deutsche Bank to close 100 retail branches and other pandemic-related news across the globe

Russia asked to apply for Sputnik V vaccine trials in India via local rep

Can't let the guard down for next 2-3 months against Covid, says V K Paul of NITI Aayog; ICMR chief sas 50% vaccine efficacy acceptable in case of respiratory viruses